Related references
Note: Only part of the references are listed.Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer
Viktoria F. Koehler et al.
THYROID (2021)
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
C. Belli et al.
ANNALS OF ONCOLOGY (2021)
Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction
M. B. Niederle et al.
BRITISH JOURNAL OF SURGERY (2021)
Clinical utility of 177Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity
Rahul V. Parghane et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
Martin B. Niederle et al.
THYROID (2020)
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
Michael C. Kreissl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives
Lucieli Ceolin et al.
ENDOCRINE-RELATED CANCER (2019)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Filetti et al.
ANNALS OF ONCOLOGY (2019)
Calcium-stimulated calcitonin - The new standard in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an old test
Martin B. Niederle et al.
BIOCHEMIA MEDICA (2018)
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M. Schlumberger et al.
ANNALS OF ONCOLOGY (2017)
Management of advanced medullary thyroid cancer
Julien Hadoux et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Medical Management of Metastatic Medullary Thyroid Cancer
Jessica E. Maxwell et al.
CANCER (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Current Understanding and Management of Medullary Thyroid Cancer
Madhuchhanda Roy et al.
ONCOLOGIST (2013)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis
Johannes A. A. Meijer et al.
CLINICAL ENDOCRINOLOGY (2010)
Calcitonin measurement in the evaluation of thyroid nodules in the United States: A cost-effectiveness and decision analysis
Kevin Cheung et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders
H Vierhapper et al.
THYROID (2005)
Sporadic versus familial medullary thyroid microcarcinoma -: A histopathologic study of 50 consecutive patients
K Kaserer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2001)
Share Paper
